We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

654 hedge funds and large institutions have $12.1B invested in State Street SPDR S&P Biotech ETF in 2020 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 233 increasing their positions, 170 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 33

55% more funds holding in top 10

Funds holding in top 10: 1117 (+6)

37% more repeat investments, than reductions

Existing positions increased: 233 | Existing positions reduced: 170

35% more capital invested

Capital invested by funds: $8.96B → $12.1B (+$3.1B)

18% more funds holding

Funds holding: 554654 (+100)

5.19% more ownership

Funds ownership: 171.15%176.34% (+5.2%)

80% less call options, than puts

Call options by funds: $883M | Put options by funds: $4.34B

Holders
654
Holders Change
+100
Holders Change %
+18.05%
% of All Funds
11.57%
Holding in Top 10
17
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+54.55%
% of All Funds
0.3%
New
138
Increased
233
Reduced
170
Closed
33
Calls
$883M
Puts
$4.34B
Net Calls
-$3.46B
Net Calls Change
-$1.53B
Name Holding Trade Value Shares
Change
Change in
Stake
PP
226
Patten & Patten
Tennessee
$1.41M +$9.61K +75 +0.8%
ACM
227
AlphaStar Capital Management
North Carolina
$1.41M -$230K -1,798 -16%
WS
228
Wedbush Securities
California
$1.4M -$551K -4,300 -30%
CCG
229
Chatham Capital Group
Georgia
$1.4M +$15.1K +118 +1%
CAG
230
Crestwood Advisors Group
Massachusetts
$1.38M -$5.12K -40 -0.4%
Bank of New York Mellon
231
Bank of New York Mellon
New York
$1.36M +$109K +853 +10%
AC
232
Asio Capital
Kentucky
$1.35M +$69.2K +540 +6%
EWA
233
Exencial Wealth Advisors
Oklahoma
$1.28M -$22.4K -175 -2%
PA
234
Parallel Advisors
California
$1.27M +$11.1K +87 +1%
KJHP
235
K.J. Harrison & Partners
Ontario, Canada
$1.27M -$897K -7,000 -44%
PBCM
236
Point Break Capital Management
Florida
$1.27M
GT
237
Glenmede Trust
Pennsylvania
$1.27M +$7.17K +56 +0.6%
SG
238
StoneX Group
New York
$1.26M +$12K +94 +1%
HDIM
239
Hanson & Doremus Investment Management
Vermont
$1.24M +$29.5K +230 +3%
IWC
240
Integrated Wealth Concepts
Massachusetts
$1.24M -$6.15K -48 -0.5%
MIC
241
Meridian Investment Counsel
California
$1.23M +$53.8K +420 +5%
UAS
242
United Asset Strategies
New York
$1.23M +$135K +1,056 +14%
RFWA
243
RPg Family Wealth Advisory
Massachusetts
$1.23M
DADC
244
D.A. Davidson & Co
Montana
$1.21M +$19K +148 +2%
PHIMC
245
Private Harbour Investment Management & Counsel
Ohio
$1.21M -$9.61K -75 -0.9%
SCA
246
Snowden Capital Advisors
New York
$1.21M -$327K -2,550 -23%
ATC
247
Argent Trust Co
Tennessee
$1.2M -$19.1K -149 -2%
MCC
248
Money Concepts Capital
Florida
$1.18M +$1.07M +8,359 New
SRC
249
Shufro Rose & Co
New York
$1.18M -$38.4K -300 -3%
HBWM
250
Hollow Brook Wealth Management
New York
$1.16M -$114K -887 -10%

XBI Hedge Fund Activity: Q4 2020 in Review

654 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2020, worth a combined $12.1B — up 35% from $8.96B a quarter earlier.

Buyers outnumbered sellers: 138 funds opened new XBI positions and 33 closed out — a net gain of 105 holders — while 233 added to existing stakes and 170 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $1.54B. The largest seller was JP Morgan Chase, cutting an estimated $1.23B.

  • 654 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2020, up from 554 in Q3 2020.
  • Funds reported $12.1B of State Street SPDR S&P Biotech ETF stock for Q4 2020, up 35% quarter-over-quarter.
  • 138 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2020 and 33 closed out, a net change of +105 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q4 2020 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.54B added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q4 2020 was JP Morgan Chase, an estimated $1.23B sold.

Based on aggregated 13F filings for Q4 2020.